title: Effect of Acarbose on Long-Term Prognosis in Acute Coronary Syndromes Patients with Newly Diagnosed Impaired Glucose Tolerance.
abstract: OBJECTIVE
  To investigate the effect of acarbose therapy on the long-term prognosis of patients with acute coronary syndromes (ACS) complicating newly diagnosed impaired glucose tolerance (IGT).
  
  
  METHODS
  135 patients hospitalized for ACS who had been newly diagnosed with IGT were randomly assigned to acarbose group (150 mg/day, n = 67) or control group (no acarbose, n = 68). All cases in each group were given the same elementary treatment. Mean follow-up was 2.3 years. The incidence of major adverse cardiovascular event (MACE) and carotid intima-middle thickness (CIMT) were statistically analyzed.
  
  
  RESULTS
  During the mean follow-up of 2.3 years, the risk of recurrent MACE in acarbose group was decreased significantly compared with that in control group (26.67% versus 46.88%, P < 0.05); at the same time, thickening of the CIMT was significantly slower than the control group ((1.28 ± 0.42) mm versus (1.51 ± 0.64) mm, P < 0.05).
  
  
  CONCLUSIONS
  Acarbose can effectively reduce the risk of MACE in ACS patients with newly diagnosed IGT, simultaneously retarding the progression of carotid intima-media thickness.
authors.affiliation: Department of Internal Medicine, School of Clinical Medicine, Yangtze University, Jingzhou, Hubei 434000, China.
authors.forename: Peng
authors.initials: P
authors.lastname: Yun
authors.affiliation: Department of Cardiology, Central Hospital of Jingzhou City, Hubei 434001, China.
authors.forename: Ai-ming
authors.initials: AM
authors.lastname: Du
authors.affiliation: Department of Cardiology, Central Hospital of Jingzhou City, Hubei 434001, China.
authors.forename: Xue-jun
authors.initials: XJ
authors.lastname: Chen
authors.affiliation: Department of Endocrinology, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei 434000, China.
authors.forename: Jing-cheng
authors.initials: JC
authors.lastname: Liu
authors.affiliation: Department of Endocrinology, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei 434000, China.
authors.forename: Hu
authors.initials: H
authors.lastname: Xiao
mesh_terms: D020909:Acarbose / Q000627:therapeutic use*; D054058:Acute Coronary Syndrome / Q000150:complications*; D000368:Aged; D002318:Cardiovascular Diseases / Q000000981:diagnostic imaging / Q000453:epidemiology*; D002339:Carotid Arteries / Q000000981:diagnostic imaging; D059168:Carotid Intima-Media Thickness; D005260:Female; D018149:Glucose Intolerance / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D065089:Glycoside Hydrolase Inhibitors / Q000627:therapeutic use*; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D011379:Prognosis
chemical_list: D065089:Glycoside Hydrolase Inhibitors; D020909:Acarbose